REGN - Alnylam Pharma slips despite plans for Alzheimer's disease study in 2022

Alnylam Pharmaceuticals (ALNY -5.0%) is trading lower despite the company’s newly announced plans to begin an early-stage study for its Alzheimer’s disease (AD) candidate, ALN-APP. Cambridge, Massachusetts-based Alnylam (NASDAQ:ALNY), focused on RNAi therapeutics, has already submitted a Clinical Trial Authorization (CTA) application to the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) in this regard. The Phase 1 trial targeted at early-onset AD is expected to get underway early next year, subject to regulatory clearance. The company plans to disclose the initial human data from the study at or around year-end 2022. According to Alnylam (ALNY), ALN-APP will be the first RNAi therapeutic to target CNS diseases. The company has joined hands with Regeneron (NASDAQ:REGN) for the development of ALN-APP after the pharma giant exercised a 50-50 option under a collaboration signed between the parties in 2019. As shown below, many companies advancing AD therapeutics have well outperformed the broader market this

For further details see:

Alnylam Pharma slips despite plans for Alzheimer’s disease study in 2022